… , our real-life study demonstrated for the first time that both pirfenidone and nintedanib are
… the decline of FVC and DLCO in a 24-month period compared with non-treated patients. …

… A total of 64 patients with IPF received treatment with nintedanib at our centre … ; all patients
returned for follow-up visits and had post-baseline followup data available for analysis. Patient …

… first real-life observational study on the safety and efficacy profile of nintedanib in patients …
In our study and in line with the phase III clinical trials, nintedanib exhibited an acceptable …

… Here, we describe our almost 10 years real-life experience … patients diagnosed with IPF
and treated with pirfenidone or … real-life study of patients with IPF treated with nintedanib and …

… Objectives: This national, multicenter, retrospective real-life study was intended to determine
the impact of nintedanib on the treatment of patients with severe IPF. Methods: All patients …

… patients, who commenced treatment with nintedanib from December 2014 to June 2016 as
part of a manufacturer funded patient … The inclusion criteria included all patients who had an …

… in a real-life setting. Objective. Our objective was to examine the safety profile and efficacy
of nintedanib even in subjects treated with anticoagulants. Clinical data of patients with IPF …

… and Nintedanib in a population of patients followed at our hospital last year. The clinical
and functional characteristics of IPF patients treated with Pirfenidone or Nintedanib were …

… the first real-life evidence on nintedanib’s effectiveness and safety on patients with SSc-ILD. …
which about half of the patients were on NTD monotherapy, in our real-life study, NTD was …

… In this study we analysed patients treated with nintedanib with no history of other antifibrotic
treatment (n = 430, 70%) and patients with no antifibrotic treatment (n = 181, 30%). The …